Glenview Capital Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Glenview Capital Management reported a $5.0 bn portfolio of 42 positions to the SEC as of the end of Q2 2026. Its largest positions are GPN, CVS, THC. During the quarter it opened Agilent Technologies and Eli Lilly and exited DXC Technology and ZoomInfo Technologies.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Glenview Capital Management has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Oct 6, 2026 · filed Oct 13, 2026 · filing ↗
Stake reported in the company · event of Aug 13, 2026 · filed Aug 17, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
What changed this quarter
50 positions with a change (12 new, 13 added to, 14 trimmed, 11 sold). 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- CVS Health−41%fewer sharesReduced15.9% → 10.0%
- Agilent Technologies+5.2 ppof portfolioNew— → 5.2%
- Thermo Fisher Scientific+150%more sharesIncreased3.3% → 6.3%
- Danaher+633%more sharesIncreased0.8% → 4.4%
- Global Payments+40%more sharesIncreased11.6% → 12.9%
- Tenet Healthcare+47%more sharesIncreased7.8% → 8.4%
- Advanced Micro Devices−54%fewer sharesReduced3.6% → 3.5%
- Meta Platforms+191%more sharesIncreased1.9% → 4.0%
- DXC Technology−2.2 ppof portfolioSold out3.0% → —
- ZoomInfo Technologies−1.9 ppof portfolioSold out2.6% → —
- Centene−41%fewer sharesReduced2.8% → 2.4%
- Eli Lilly+1.4 ppof portfolioNew— → 1.4%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Global PaymentsGPN12.9%
- CVS HealthCVS10.0%
- Tenet HealthcareTHC8.4%
- Thermo Fisher ScientificTMO6.3%
- Amazon.comAMZN6.1%
- Agilent TechnologiesA5.2%
- DanaherDHR4.4%
- Meta PlatformsMETA4.0%
- Advanced Micro DevicesAMD3.5%
- TEVA Pharmaceutical IndustriesTEVA3.4%
- ViatrisVTRS3.1%
- UBER TechnologiesUBER2.6%
- CenteneCNC2.4%
- Butterfly NetworkBFLY2.4%
- Cigna GroupCI2.3%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 55%
- ● Financials 15%
- ● Consumer Discretionary 12%
- ● Information Technology 9%
- ● Communication Services 4%
- ● Industrials 4%
- ● Materials 1%
- ● Energy 1%
How its portfolio changed (8 quarters)
Q2 2026: 42
Q2 2026: 64%
Q2 2026: 28.7%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Declared options (3)
Besides stocks, Glenview Capital Management declared 2 puts (they gain if the stock falls) and 1 call (they gain if it rises) with a notional of $486M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- PUTiShares Russell 2000 ETFIWM$276M
- PUTState Str Spdr S&P 500 ETF TSPYnew this quarter$194M
- CALLAgilent TechnologiesAnew this quarter$15.5M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Sep 15, 2026 (high confidence).
The data, as reported: GLENVIEW CAPITAL MANAGEMENT, LLC (CRD 137640): 7.B private funds: 6 hedge (gross assets $6.5 bn); 5.D assets by client type: pooled vehicles 100% (of $6.4 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Maple Rock Capital PartnersInvestment firm · $5.1 bn
- Akre Capital ManagementInvestment firm · $5.1 bn
- Skye Global ManagementInvestment firm · $5.1 bn
- MFN Partners ManagementInvestment firm · $4.8 bn
- Sachem Head Capital ManagementInvestment firm · $4.8 bn
- Stockbridge PartnersInvestment firm · $4.8 bn